Angel M. Carcaboso

List of Publications by Year
in descending order

99 papers	6,341 citations	101384 36 h-index	76769 74 g-index
105 all docs	105 docs citations	105 times ranked	9781 citing authors

#	Article	IF	Citations
1	Repurposing Vandetanib plus Everolimus for the Treatment ofACVR1-Mutant Diffuse Intrinsic Pontine Glioma. Cancer Discovery, 2022, 12, 416-431.	7.7	25
2	SPARC-mediated long-term retention of nab-paclitaxel in pediatric sarcomas. Journal of Controlled Release, 2022, 342, 81-92.	4.8	12
3	PPM1D mutations are oncogenic drivers of de novo diffuse midline glioma formation. Nature Communications, 2022, 13, 604.	5.8	22
4	Identification of immunosuppressive factors in retinoblastoma cell secretomes and aqueous humor from patients. Journal of Pathology, 2022, , .	2.1	3
5	Treatment of Retinoblastoma: What Is the Latest and What Is the Future. Frontiers in Oncology, 2022, 12, 822330.	1.3	30
6	AC-265347 Inhibits Neuroblastoma Tumor Growth by Induction of Differentiation without Causing Hypocalcemia. International Journal of Molecular Sciences, 2022, 23, 4323.	1.8	1
7	Amphiphilic Polymeric Nanoparticles Modified with a Protease-Resistant Peptide Shuttle for the Delivery of SN-38 in Diffuse Intrinsic Pontine Glioma. ACS Applied Nano Materials, 2021, 4, 1314-1329.	2.4	15
8	PDX-Derived Ewingâ€™s Sarcoma Cells Retain High Viability and Disease Phenotype in Alginate Encapsulated Spheroid Cultures. Cancers, 2021, 13, 879.	1.7	6
9	Evofosfamide Is Effective against Pediatric Aggressive Glioma Cell Lines in Hypoxic Conditions and Potentiates the Effect of Cytotoxic Chemotherapy and Ionizing Radiations. Cancers, 2021, 13, 1804.	1.7	5
10	Prognostic value of patientâ€derived xenograft engraftment in pediatric sarcomas. Journal of Pathology: Clinical Research, 2021, 7, 338-349.	1.3	10
11	Effective Detection and Monitoring of Glioma Using [18F]FPIA PET Imaging. Biomedicines, 2021, 9, 811.	1.4	5
12	Selective inhibition of HDAC6 regulates expression of the oncogenic driver EWSR1-FLI1 through the EWSR1 promoter in Ewing sarcoma. Oncogene, 2021, 40, 5843-5853.	2.6	10
13	A high-risk retinoblastoma subtype with stemness features, dedifferentiated cone states and neuronal/ganglion cell gene expression. Nature Communications, 2021, 12, 5578.	5.8	45
14	Multifunctional silica-coated mixed polymeric micelles for integrin-targeted therapy of pediatric patient-derived glioblastoma. Materials Science and Engineering C, 2021, 128, 112261.	3.8	11
15	Senescence Induced by BMI1 Inhibition Is a Therapeutic Vulnerability in H3K27M-Mutant DIPG. Cell Reports, 2020, 33, 108286.	2.9	39
16	In vivo CRISPR/Cas9 targeting of fusion oncogenes for selective elimination of cancer cells. Nature Communications, 2020, 11, 5060.	5.8	60
17	LIN28B Underlies the Pathogenesis of a Subclass of Ewing Sarcoma. Cell Reports, 2020, 30, 4567-4583.e5.	2.9	20
18	Reciprocal H3.3 gene editing identifies K27M and G34R mechanisms in pediatric glioma including NOTCH signaling. Communications Biology, 2020, 3, 363.	2.0	32

#	Article	IF	Citations
19	OKlahoma Nitrone-007: novel treatment for diffuse intrinsic pontine glioma. Journal of Translational Medicine, 2020, 18, 424.	1.8	7
20	RING1B recruits EWSR1-FLI1 and cooperates in the remodeling of chromatin necessary for Ewing sarcoma tumorigenesis. Science Advances, 2020, 6, .	4.7	24
21	Combined treatment with CBP and BET inhibitors reverses inadvertent activation of detrimental super enhancer programs in DIPG cells. Cell Death and Disease, 2020, 11, 673.	2.7	36
22	Amphiphilic Polymeric Nanoparticles Modified with a Retro-Enantio Peptide Shuttle Target the Brain of Mice. Chemistry of Materials, 2020, 32, 7679-7693.	3.2	18
23	Treatment-driven selection of chemoresistant Ewing sarcoma tumors with limited drug distribution. Journal of Controlled Release, 2020, 324, 440-449.	4.8	7
24	Development of a human in vitro bloodâ€“brain tumor barrier model of diffuse intrinsic pontine glioma to better understand the chemoresistance. Fluids and Barriers of the CNS, 2020, 17, 37.	2.4	27
25	Optimizing the storage of chemotherapeutics for ophthalmic oncology: stability of topotecan solution for intravitreal injection. Ophthalmic Genetics, 2020, 41, 397-400.	0.5	2
26	Proteomic Profiling of Retinoblastoma-Derived Exosomes Reveals Potential Biomarkers of Vitreous Seeding. Cancers, 2020, 12, 1555.	1.7	33
27	Combined Therapy of AXL and HDAC Inhibition Reverses Mesenchymal Transition in Diffuse Intrinsic Pontine Glioma. Clinical Cancer Research, 2020, 26, 3319-3332.	3.2	44
28	Genomic and Transcriptomic Tumor Heterogeneity in Bilateral Retinoblastoma. JAMA Ophthalmology, 2020, 138, 569.	1.4	17
29	Characterization of the Bloodâ€“Brain Barrier Integrity and the Brain Transport of SN-38 in an Orthotopic Xenograft Rat Model of Diffuse Intrinsic Pontine Glioma. Pharmaceutics, 2020, 12, 399.	2.0	18
30	Epigenetic loss of RNA-methyltransferase NSUN5 in glioma targets ribosomes to drive a stress adaptive translational program. Acta Neuropathologica, 2019, 138, 1053-1074.	3.9	106
31	PPM1D mutations silence NAPRT geneÂexpression and confer NAMPT inhibitor sensitivity in glioma. Nature Communications, 2019, 10, 3790.	5.8	54
32	Selective Accumulation of Galactomannan Amphiphilic Nanomaterials in Pediatric Solid Tumor Xenografts Correlates with GLUT1 Gene Expression. ACS Applied Materials & Interfaces, 2019, 11, 38483-38496.	4.0	21
33	Therapeutic targeting of the RB1 pathway in retinoblastoma with the oncolytic adenovirus VCN-01. Science Translational Medicine, 2019, 11, .	5.8	67
34	Identification of Novel RAS Signaling Therapeutic Vulnerabilities in Diffuse Intrinsic Pontine Gliomas. Cancer Research, 2019, 79, 4026-4041.	0.4	16
35	Radiosensitization by Histone H3 Demethylase Inhibition in Diffuse Intrinsic Pontine Glioma. Clinical Cancer Research, 2019, 25, 5572-5583.	3.2	52
36	Conservative management of retinoblastoma: Challenging orthodoxy without compromising the state of metastatic grace. â€œAlive, with good vision and no comorbidityâ€• Progress in Retinal and Eye Research, 2019, 73, 100764.	7.3	123

#	Article	IF	Citations
37	ALK2 inhibitors display beneficial effects in preclinical models of ACVR1 mutant diffuse intrinsic pontine glioma. Communications Biology, 2019, 2, 156.	2.0	73
38	Tridimensional Retinoblastoma Cultures as Vitreous Seeds Models for Live-Cell Imaging of Chemotherapy Penetration. International Journal of Molecular Sciences, 2019, 20, 1077.	1.8	22
39	Efficacy of systemic temozolomideâ€activated phageâ€targeted gene therapy in human glioblastoma. EMBO Molecular Medicine, 2019, 11, .	3.3	51
40	ACVR1C/SMAD2 signaling promotes invasion and growth in retinoblastoma. Oncogene, 2019, 38, 2056-2075.	2.6	33
41	Preclinical Efficacy of Endoglin-Targeting Antibodyâ€"Drug Conjugates for the Treatment of Ewing Sarcoma. Clinical Cancer Research, 2019, 25, 2228-2240.	3.2	44
42	Glucosylated nanomicelles target glucose-avid pediatric patient-derived sarcomas. Journal of Controlled Release, 2018, 276, 59-71.	4.8	27
43	Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq. Science, 2018, 360, 331-335.	6.0	461
44	Effect of growing glycosylation extents on the self-assembly and active targeting in vitro of branched poly(ethylene oxide)-poly(propylene oxide) block copolymers. Applied Materials Today, 2018, 11, 57-69.	2.3	16
45	A Novel Method for Rapid Molecular Subgrouping of Medulloblastoma. Clinical Cancer Research, 2018, 24, 1355-1363.	3.2	24
46	Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling. Nature, 2018, 553, 101-105.	13.7	170
47	NG2 antigen is involved in leukemia invasiveness and central nervous system infiltration in MLL-rearranged infant B-ALL. Leukemia, 2018, 32, 633-644.	3.3	35
48	Novel and shared neoantigen derived from histone 3 variant H3.3K27M mutation for glioma T cell therapy. Journal of Experimental Medicine, 2018, 215, 141-157.	4.2	186
49	DIPG-29. PRECLINICAL EFFICACY OF COMBINED ACVR1 AND PI3K/mTOR INHIBITION IN DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG). Neuro-Oncology, 2018, 20, i54-i55.	0.6	4
50	Functional diversity and cooperativity between subclonal populations of pediatric glioblastoma and diffuse intrinsic pontine glioma cells. Nature Medicine, 2018, 24, 1204-1215.	15.2	133
51	MELK Inhibition in Diffuse Intrinsic Pontine Glioma. Clinical Cancer Research, 2018, 24, 5645-5657.	3.2	30
52	Immune Response Generated With the Administration of Autologous Dendritic Cells Pulsed With an Allogenic Tumoral Cell-Lines Lysate in Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma. Frontiers in Oncology, 2018, 8, 127.	1.3	31
53	CSF H3F3A K27M circulating tumor DNA copy number quantifies tumor growth and in vitro treatment response. Acta Neuropathologica Communications, 2018, 6, 80.	2.4	50
54	Tissue Compatibility of SNâ€38â€Loaded Anticancer Nanofiber Matrices. Advanced Healthcare Materials, 2018, 7, e1800255.	3.9	5

#	Article	IF	Citations
55	The combination of epigenetic drugs SAHA and HCI-2509 synergistically inhibits EWS-FLI1 and tumor growth in Ewing sarcoma. Oncotarget, 2018, 9, 31397-31410.	0.8	27
56	EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas. Nature Medicine, 2017, 23, 483-492.	15.2	392
57	Targeted drug distribution in tumor extracellular fluid of GD2-expressing neuroblastoma patient-derived xenografts using SN-38-loaded nanoparticles conjugated to the monoclonal antibody 3F8. Journal of Controlled Release, 2017, 255, 108-119.	4.8	35
58	Evaluation of a novel antibody to define histone 3.3 G34R mutant brain tumours. Acta Neuropathologica Communications, 2017, 5, 45.	2.4	26
59	Oncolytic Herpes Simplex Virus Inhibits Pediatric Brain Tumor Migration and Invasion. Molecular Therapy - Oncolytics, 2017, 5, 75-86.	2.0	22
60	Preclinical evaluation of convection-enhanced delivery of liposomal doxorubicin to treat pediatric diffuse intrinsic pontine glioma and thalamic high-grade glioma. Journal of Neurosurgery: Pediatrics, 2017, 19, 518-530.	0.8	23
61	Deubiquitinase USP13 maintains glioblastoma stem cells by antagonizing FBXL14-mediated Myc ubiquitination. Journal of Experimental Medicine, 2017, 214, 245-267.	4.2	123
62	Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma. Cancer Cell, 2017, 32, 520-537.e5.	7.7	716
63	Increased delivery of chemotherapy to the vitreous by inhibition of the blood-retinal barrier. Journal of Controlled Release, 2017, 264, 34-44.	4.8	11
64	Heterogeneity of neuroblastoma cell identity defined by transcriptional circuitries. Nature Genetics, 2017, 49, 1408-1413.	9.4	331
65	Pre-Clinical Study of Panobinostat in Xenograft and Genetically Engineered Murine Diffuse Intrinsic Pontine Glioma Models. PLoS ONE, 2017, 12, e0169485.	1.1	130
66	Highlights of Children with Cancer UKâ€™s Workshop on Drug Delivery in Paediatric Brain Tumours. Ecancermedicalscience, 2016, 10, 630.	0.6	2
67	Translational Pharmacokineticâ€Pharmacodynamic Modeling and Simulation: Optimizing 5â€Fluorouracil Dosing in Children With Pediatric Ependymoma. CPT: Pharmacometrics and Systems Pharmacology, 2016, 5, 211-221.	1.3	6
68	Preclinical platform of retinoblastoma xenografts recapitulating human disease and molecular markers of dissemination. Cancer Letters, 2016, 380, 10-19.	3.2	22
69	Bevacizumab Targeting Diffuse Intrinsic Pontine Glioma: Results of 89Zr-Bevacizumab PET Imaging in Brain Tumor Models. Molecular Cancer Therapeutics, 2016, 15, 2166-2174.	1.9	51
70	SN-38-loaded nanofiber matrices for local control of pediatric solid tumors after subtotal resection surgery. Biomaterials, 2016, 79, 69-78.	5.7	40
71	Schedule-Dependent Antiangiogenic and Cytotoxic Effects of Chemotherapy on Vascular Endothelial and Retinoblastoma Cells. PLoS ONE, 2016, 11, e0160094.	1.1	18
72	RING1B contributes to Ewing sarcoma development by repressing the NaV1.6 sodium channel and the NF-ÎºB pathway, independently of the fusion oncoprotein. Oncotarget, 2016, 7, 46283-46300.	0.8	12

#	Article	IF	Citations
73	Cinacalcet inhibits neuroblastoma tumor growth and upregulates cancer-testis antigens. Oncotarget, 2016, 7, 16112-16129.	0.8	19
74	The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin. Oncotarget, 2015, 6, 18875-18890.	0.8	74
75	Cell migration in paediatric glioma; characterisation and potential therapeutic targeting. British Journal of Cancer, 2015, 112, 693-703.	2.9	30
76	Combined Microdialysis-Tumor Homogenate Method for the Study of the Steady State Compartmental Distribution of a Hydrophobic Anticancer Drug in Patient-Derived Xenografts. Pharmaceutical Research, 2015, 32, 2889-2900.	1.7	11
77	OCULAR PHARMACOLOGY OF TOPOTECAN AND ITS ACTIVITY IN RETINOBLASTOMA. Retina, 2014, 34, 1719-1727.	1.0	38
78	Nanomedicines in the future of pediatric therapy. Advanced Drug Delivery Reviews, 2014, 73, 140-161.	6.6	49
79	Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma. Nature Genetics, 2014, 46, 457-461.	9.4	423
80	Intraâ€arterial chemotherapy for retinoblastoma. Challenges of a prospective study. Acta Ophthalmologica, 2014, 92, 209-215.	0.6	27
81	An Integrated InÂVitro and InÂVivo High-Throughput Screen Identifies Treatment Leads for Ependymoma. Cancer Cell, 2011, 20, 384-399.	7.7	105
82	Magnetic Resonance Imagingâ€“Guided Microdialysis Cannula Implantation in a Spontaneous High-Grade Glioma Murine Model. Journal of Pharmaceutical Sciences, 2011, 100, 4210-4214.	1.6	12
83	Subconjunctival carboplatin and systemic topotecan treatment in preclinical models of retinoblastoma. Cancer, 2011, 117, 421-434.	2.0	46
84	Role of ATP-Binding Cassette and Solute Carrier Transporters in Erlotinib CNS Penetration and Intracellular Accumulation. Clinical Cancer Research, 2011, 17, 89-99.	3.2	97
85	New old challenges in tuberculosis: Potentially effective nanotechnologies in drug delivery. Advanced Drug Delivery Reviews, 2010, 62, 547-559.	6.6	241
86	Tyrosine Kinase Inhibitor Gefitinib Enhances Topotecan Penetration of Gliomas. Cancer Research, 2010, 70, 4499-4508.	0.4	68
87	Episcleral Implants for Topotecan Delivery to the Posterior Segment of the Eye. , 2010, 51, 2126.		47
88	Novel long-term anticonvulsant treatment with gabapentin without causing memory impairment in mice. Epilepsy and Behavior, 2010, 17, 157-164.	0.9	3
89	A Phase I Study of Periocular Topotecan in Children with Intraocular Retinoblastoma. , 2009, 50, 1492.		48
90	Compartment-Specific Roles of ATP-Binding Cassette Transporters Define Differential Topotecan Distribution in Brain Parenchyma and Cerebrospinal Fluid. Cancer Research, 2009, 69, 5885-5892.	0.4	52

#	Article	IF	Citations
91	Drug delivery systems in HIV pharmacotherapy: What has been done and the challenges standing ahead. Journal of Controlled Release, 2009, 138, 2-15.	4.8	98
92	Indinavir-Loaded pH-Sensitive Microparticles for Taste Masking: Toward Extemporaneous Pediatric Anti-HIV/AIDS Liquid Formulations with Improved Patient Compliance. AAPS PharmSciTech, 2009, 10, 1-6.	1.5	52
93	In vitro/in vivo characterization of melt-molded gabapentin-loaded poly(epsilon-caprolactone) implants for sustained release in animal studies. European Journal of Pharmaceutics and Biopharmaceutics, 2008, 70, 666-673.	2.0	18
94	Adjuvant activity of polymer microparticles and Montanide ISA 720 on immune responses to Plasmodium falciparum MSP2 long synthetic peptides in mice. Vaccine, 2007, 25, 877-885.	1.7	36
95	Topotecan Vitreous Levels after Periocular or Intravenous Delivery in Rabbits: An Alternative for Retinoblastoma Chemotherapy. , 2007, 48, 3761.		54
96	Biocompatibility Evaluation of Different Alginates and Alginate-Based Microcapsules. Biomacromolecules, 2005, 6, 927-931.	2.6	109
97	Enhancing Immunogenicity and Reducing Dose of Microparticulated Synthetic Vaccines: Single Intradermal Administration. Pharmaceutical Research, 2004, 21, 121-126.	1.7	28
98	Potent, long lasting systemic antibody levels and mixed Th1/Th2 immune response after nasal immunization with malaria antigen loaded PLGA microparticles. Vaccine, 2004, 22, 1423-1432.	1.7	83
99	Immune response after oral administration of the encapsulated malaria synthetic peptide SPf66. International Journal of Pharmaceutics, 2003, 260, 273-282.	2.6	43